JP2021521828A5 - - Google Patents
Info
- Publication number
- JP2021521828A5 JP2021521828A5 JP2020559481A JP2020559481A JP2021521828A5 JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5 JP 2020559481 A JP2020559481 A JP 2020559481A JP 2020559481 A JP2020559481 A JP 2020559481A JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- salt
- hydroxycitric acid
- cultured
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661941P | 2018-04-24 | 2018-04-24 | |
| US62/661,941 | 2018-04-24 | ||
| PCT/US2019/028513 WO2019209715A1 (en) | 2018-04-24 | 2019-04-22 | Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521828A JP2021521828A (ja) | 2021-08-30 |
| JP2021521828A5 true JP2021521828A5 (cg-RX-API-DMAC10.html) | 2022-05-02 |
| JP7342030B2 JP7342030B2 (ja) | 2023-09-11 |
Family
ID=66641471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559481A Active JP7342030B2 (ja) | 2018-04-24 | 2019-04-22 | ヒドロキシクエン酸および／またはその塩を使用してｔ細胞集団を産生する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12415845B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3784774B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7342030B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN112262212B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019260656B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3097858A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019209715A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3959305A1 (en) * | 2019-04-26 | 2022-03-02 | Allogene Therapeutics, Inc. | Methods of manufacturing allogeneic car t cells |
| WO2021222479A1 (en) * | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4178590A4 (en) * | 2020-07-09 | 2024-09-25 | The Board of Trustees of the Leland Stanford Junior University | MULTIPARALLEL ANALYSIS OF T-CELL THERAPIES |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| CA2674445C (en) | 2007-01-12 | 2016-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| US8785601B2 (en) | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| JP5934099B2 (ja) | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| US9345748B2 (en) | 2010-09-21 | 2016-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| ES2835200T3 (es) | 2012-05-22 | 2021-06-22 | Us Health | Uso médico de células que comprenden receptores de células T anti-NY-ESO-1 |
| US9879065B2 (en) | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| CN104822705B (zh) | 2012-10-24 | 2019-07-12 | 美国卫生和人力服务部 | M971嵌合抗原受体 |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| CN110511960B (zh) | 2013-07-15 | 2023-05-23 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| CA2936984A1 (en) | 2014-01-24 | 2015-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors |
| PT3149031T (pt) | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
| CN107075479A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| ES2924709T3 (es) | 2014-10-02 | 2022-10-10 | Us Health | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer |
| US20170312200A1 (en) * | 2014-10-29 | 2017-11-02 | Showa Denko K.K. | An agent for improving mitochondrial function |
| GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
| US20190321314A1 (en) | 2016-09-15 | 2019-10-24 | Memorial Sloan Kettering Cancer Center | Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders |
-
2019
- 2019-04-22 CN CN201980037634.5A patent/CN112262212B/zh active Active
- 2019-04-22 AU AU2019260656A patent/AU2019260656B2/en active Active
- 2019-04-22 CA CA3097858A patent/CA3097858A1/en active Pending
- 2019-04-22 JP JP2020559481A patent/JP7342030B2/ja active Active
- 2019-04-22 CN CN202410809055.0A patent/CN118726256A/zh active Pending
- 2019-04-22 WO PCT/US2019/028513 patent/WO2019209715A1/en not_active Ceased
- 2019-04-22 US US17/050,045 patent/US12415845B2/en active Active
- 2019-04-22 EP EP19726230.6A patent/EP3784774B1/en active Active
-
2025
- 2025-08-18 US US19/302,338 patent/US20260042814A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nallasamy et al. | Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis | |
| Nojima et al. | In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo | |
| JP6022667B2 (ja) | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ | |
| US20210085719A1 (en) | Bispecific car t-cells for solid tumor targeting | |
| Terabe et al. | Role of IL-13 in regulation of anti-tumor immunity and tumor growth | |
| CN103756964B (zh) | 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法 | |
| TW202020141A (zh) | 一種用於nk細胞體外擴增的培養基體系及nk細胞體外擴增的方法 | |
| WO2020057486A1 (zh) | 经修饰的t细胞、其制备方法及用途 | |
| IL274293B2 (en) | Process for generating therapeutic compositions of engineered cells | |
| JP2017533706A5 (cg-RX-API-DMAC10.html) | ||
| JP2020534839A5 (cg-RX-API-DMAC10.html) | ||
| CN109121413A (zh) | 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法 | |
| JP2016524914A5 (cg-RX-API-DMAC10.html) | ||
| JP2012521215A5 (cg-RX-API-DMAC10.html) | ||
| Lv et al. | γδT cells, a key subset of T cell for cancer immunotherapy | |
| WO2019206326A1 (zh) | 改进的t细胞治疗方法 | |
| Huang et al. | T cell immune response within B-cell follicles | |
| Xiao et al. | Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity | |
| CN101313061A (zh) | 扩增双阴性t细胞的方法 | |
| Fu et al. | Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells | |
| Koppers et al. | Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer | |
| Lin et al. | Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy | |
| CN112262212B (zh) | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 | |
| Durgin et al. | Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence | |
| Amiji et al. | Cancer Immunology and Immunotherapy: Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy |